The authors employed a novel approach to identify therapeutics effective in Alzheimer disease (AD). The 5′ untranslated region (5′UTR) of the mRNA of AD amyloid precursor protein (APP) is a significant regulator of the levels of the APP holoprotein and amyloid beta (Aβ) peptide in the central nervous system. The authors generated stable neuroblastoma SH-SY5Y transfectants that express luciferase under the translational control of the 146-nucleotide APP mRNA 5′UTR and green fluorescent protein (GFP) driven by a viral internal ribosomal entry site. Using a high-throughput screen (HTS), they screened for the effect of 110,000 compounds obtained from the library of the Laboratory for Drug Discovery on Neurodegeneration (LDDN) on the APP mRNA 5′UTR-controlled translation of the luciferase reporter. This screening yielded several nontoxic specific inhibitors of APP mRNA 5′UTR-driven luciferase that had no effect on the GFP expression in the stable SH-SY5Y transfectants. Moreover, these compounds either did not inhibit or inhibited to a much lower extent the expression of the luciferase reporter regulated by a prion protein (PrP) mRNA 5′UTR, used as an alternative mRNA structure to counterscreen APP mRNA 5′UTR in stably transfected SH-SY5Y cell lines. The hits obtained from this robust, specific, and highly quantitative HTS will be characterized to identify agents that may be developed into useful future therapeutic agents to limit APP translation and Aβ production for AD. (Journal of Biomolecular Screening 2006:469-480) 
INTRODUCTION
A LZHEIMER DISEASE (AD) is the most common form of dementia and has affected about 20 to 30 million people worldwide. 1 Although therapeutics for the disease focused on multiple targets have developed, 2 no disease-modifying drugs exist. Therefore, novel approaches to the development of additional therapeutics are still required.
The amyloid precursor protein (APP), a membranespanning glycoprotein of 695 to 770 amino acids that is widely expressed in neurons and nonneuronal cells, 3 undergoes proteolytic processing by the amyloidogenic and the nonamyloidogenic pathways. 4 In the amyloidogenic pathway, APP is cleaved by the βand γ-secretases 5 to release the amyloid β (Aβ) peptide, which aggregates to form amyloid plaques, 6 the characteristic pathological hallmarks for AD. On the other hand, α-secretase cleaves APP in the nonamyloidogenic pathway to release the secreted neuroprotective APP from the cell surface. 7 In humans, the expression of the APP gene is regulated by the proximal promoter region (-46/-1) and the 5′ untranslated region (5′UTR; +1/+147). 8 The APP mRNA 5′UTR sequence is rich in GC (80%) and is predicted to fold into a single stable RNA stem-loop structure (∆G = -54.9 kCal/mol). 9,10 A unique CAGA sequence, "amyloid" (+83/+86), exists only in the APP gene from the amyloid plaque-forming species and is absent in all APP-like proteins (APLP1 and APLP2). 8 A functional interleukin-1 (IL-1)-responsive acute box translational enhancer sequence (+55 to +144) 11, 12 and an iron-responsive element (IRE) 13 immediately upstream of the acute box element (+51 to +94) from the 5′-cap site, each exist in the APP precursor transcript. IL-1 enhances the interaction between the iron-regulatory proteins (IRP-1 and IRP-2) and the RNA secondary structure in the APP mRNA 5′UTR. This regulation is consistent with the cytoprotective acute-phase induction of APP. These regulatory sites in the 5′UTR of the human APP mRNA, such as the acute box element, the CAGA box, the IRE, and a transforming growth factor-β-responsive element were shown to control APP expression and provide suitable and specific targets for therapeutics for AD. 8, [10] [11] [12] [13] [14] Seeking to target the RNA structures 15 is a therapeutic strategy, 16 and the design and development of drugs against RNA targets have revealed much about RNA-protein interactions. Small molecules have even been selected to bind to specific RNA aptamers 17 that inhibited translation of a downstream gene both in vitro and in vivo. RNA has also been therapeutically targeted to slow the progression of HIV infection by inhibiting the binding of HIV-1 transactivator protein transduction domain to the 5′ bulge of the transactivation responsive RNA stem-loop in the HIV genome. [17] [18] [19] Previously, a screen of 1200 Food and Drug Administration (FDA)-approved compounds that used transiently transfected neuroblastoma cells identified 17 leads that limited APP mRNA 5′UTR-driven translation. 20, 21 Of these, paroxetine (serotonin reuptake inhibitor) and dimercaptopropanol (metal chelator) reduced expression of APP holoprotein and the secretion of Aβ (1-42), 21, 22 whereas the other drugs of the same class showed no effect. Azithromycin was found to alter APP processing without changing the expression of APLP1 and APLP2 in SH-SY5Y cells. 21 A pilot study further indicated that paroxetine reduced amyloid burden in TgCRNDS mice, a transgenic mouse model for AD. 23 Here we report development of a high-throughput screen (HTS) with 110,000 compounds from the library of the Laboratory for Drug Discovery on Neurodegeneration (LDDN) to identify APP mRNA 5′UTR-directed compounds. For this HTS, we generated stable neuroblastoma SH-SY5Y transfectants that expressed luciferase, used for the assay, under the translational control of 146-nucleotide APP mRNA 5′UTR and a green fluorescent protein (GFP) that served as the internal specificity control driven by a viral internal ribosomal entry site (IRES).
MATERIALS AND METHODS

Reagents
Dulbecco's Modified Eagle medium (DMEM) was purchased from Cambrex (Walkersville, MD), fetal bovine serum (FBS) and kanamycin from Sigma-Aldrich (St. Louis, MO), penicillinstreptomycin (penn-strep) from Bio-Whittaker (Walkersville, MD), and geneticin from Invitrogen (Carlsbad, CA). All restriction enzymes and modifying enzymes were purchased from New England Biolabs (Beverly, MA).
Cell culture
The SH-SY5Y human neuroblastoma cell line was purchased from American Type Culture Collection (Manassas, VA). The cells were maintained in complete growth medium containing DMEM, 10% FBS, and 1% penn-strep. Stably transfected cells were cultured in this medium supplemented with 300 µg/ml of geneticin.
Generation of DNA constructs: pIRES(APP mRNA 5′ ′UTR) and pIRES(PrP mRNA 5′ ′UTR)
The PGAL construct containing the full-length 146-nucleotide APP mRNA 5′UTR upstream from the luciferase gene start codon was prepared as described previously. 20 This firefly (Photinus pyralis) luciferase reporter gene is translationally regulated by the APP mRNA 5′UTR that bears the IL-1-responsive element and an additional 55 nucleotides immediately downstream from the 5′-cap site of APP mRNA that had the novel IRE within it.
To generate an APP mRNA 5′UTR-driven luciferase reporter gene construct with GFP as an internal specificity control, we excised the APP mRNA 5′UTR luciferase fragment from the PGAL construct by Hind III and Xba I digestion. The excised fragment was blunt ended by klenow DNA polymerase I treatment. This fragment was then ligated to Sma1 digested linearized pIRES-EGFP vector (Clontech, Mountain View, CA). The plasmid construct was amplified in bacteria in medium containing kanamycin. This construct was named pIRES(APP mRNA 5′UTR). The colonies were isolated, and the PCR (Qiagen, Valencia, CA)-generated cassette was confirmed from band size after treatment with BamH I restriction enzyme. Bidirectional DNA sequencing confirmed the identity of the clones using GL2 and RV3 primers, the sequencing primers for PGL3 20 (Promega, Madison, WI). The construct obtained permits both the gene of interest (i.e., APP mRNA 5′UTR driven by luciferase) and the EGFP gene to be translated from a single bicistronic mRNA ( Fig. 1A, B ).
Two complementary oligonucleotides (Sigma) were annealed to each other (30 µg of each in a total volume of 1 ml of 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA) at 95° C for 1 min and then allowed to cool slowly to room temperature to form the double-stranded 5′UTR of PrP variant 2. [24] [25] [26] The oligonucleotide sequences are AGCTTCCCCCTCGGCCC CGCGCG-TCGCCTGTCCTCCGAGCCAGTCGCTGACA GCCGCGGCGCCGCGAGCTTCTCCTCTCC-TCACGACC-GAGAGCAGTCATTAC (sense) and CATGGTAATGACTGC TCTCGGTCGT-GAGGAGAGGAGAAGCTCGCGGCGC-C G C G G C T G T C AG C G AC T G G C T C G G AG G AC AG -GCGACGCGCGGGGCCGAGGGGGA (antisense). The annealed PrP 5′UTR oligonucleotide was first cloned into PGAL. This clone was then digested with Hind III and Xba I, blunt ended and cloned into Sma I digested pIRES-EGFP vector as described before. This was named pIRES(PrP mRNA 5′UTR) construct (Fig. 1C, D) .
Generation of stable SH-SY5Y transfectants
The SH-SY5Y neuroblastoma cell line was transfected with AMAXA cell line Nucleofactor kit V (AMAXA Biosystems, Gaithersburg, MD) following the manufacturer's instructions. Briefly, the cells were plated in 100-mm culture dishes and grown to 75% to 80% confluence then trypsinized, and a total of 1.5 × 10 6 cells were centrifuged and resuspended in 100 µl of nucleofactor TM solution V (0.5 ml supplement mixed with 2.25 ml nucleofactor TM solution provided with the AMAXA kit). A total of 2 to 10 µg of plasmid (pIRES APP mRNA 5′UTR)/(pIRES PrP mRNA 5′UTR) was electroporated using loid precursor protein (APP) mRNA 5′untranslated region (5′UTR). Note that the APP mRNA 5′UTR sequence is highly GC rich (80%) and is predicted to fold into a single stable RNA stem-loop structure (∆G = -54.9 KCal/mol) that is an important regulator for APP gene expression. (B) The pIRES(APP mRNA 5′UTR) construct. This construct was generated by ligating the 146-nucleotide of APP 5′UTR and luciferase fragment excised from PGAL construct 20 into the linearized pIRES-EGFP vector. The APP mRNA 5′UTR-driven luciferase reporter gene construct incorporated EGFP as an internal specificity control. (C) RNA secondary structure prediction for bases from +1 to +97 of the 97-nucleotide prion protein (PrP) mRNA 5′UTR (∆G = -32.9 kCal/mol). (D) pIRES(PrP mRNA 5′UTR) construct. This construct was generated by 2-step cloning: 1) removal of APP 5′UTR from PGAL and inserting the PrP 5′UTR (variant 2) in its place into the PGAL and 2) excising the PrP 5′UTR luciferase fragment from PGAL and ligating this into the linearized pIRES-EGFP. Use of this construct increased screening specificity.
the G-04 program of an AMAXA electroporator according to the manufacturer's instructions. A total of 2 µg of pIRES-EGFP plasmid (Clontech) was transfected into the cells as a positive control. The cells were then cultured in complete growth medium. After 48 h, the medium was removed and replaced with geneticin-supplemented medium for selection of stable clones; the medium was then changed regularly every 4 to 5 days. Within 10 days, a mixed population with 70% of pIRES (APP mRNA 5′UTR)/pIRES(PrP mRNA 5′UTR)-transfected cells was obtained, which was then split and a stock maintained. Transfection efficiency was determined by counting GFPpositive cells observed under a Nikon TE 300 fluorescence microscope with GFP filters (excitation = 465-495, emission = 515-555). Images were taken under a 20× magnification objective lens.
Assay optimization
Optimization for cell density in a 384-well format and luciferase substrate was performed. pIRES(APP mRNA 5′UTR)/pIRES(PrP mRNA 5′UTR)-transfected stable cells were serially diluted from 10,000 to 500 cells per well (40 µl). The cells were added to the 384-well white or black plates with or without clear bottoms (Nalgene Nunc, Rochester, NY) to optimize the cell number and type of plate suitable for the assay. Untransfected SH-SY5Y cells served as negative controls to the luciferase readings and took into account the background effects. The cells were added using 16-channelled pipettes. Phenol red-free medium was used for the dilution because colored medium reduced the luciferase assay signals. The plates were incubated for 2 h in humidified 5% CO 2 /95% air incubator at 37°C, and when the cells had attached to the bottom of the plate, as observed through clear plates, 10 µl of serum-free medium with 0.7% DMSO (0.7% DMSO being the solvent for the HTS compound library) was added, and the plates were sealed with gas-permeable aeraseals (Bellco Glass, Vineland, NJ). At 48 h of incubation in a humidified 5% CO 2 air incubator at 37°C, the plates were allowed to adapt to room temperature for 30 min. Then, 25 µl of luciferase substrate was added to each well and incubated for 30 min for complete cell lysis. The luciferase expression of the transfected cells was determined by measuring luminescence on an LJL Analyst (Molecular Devices, Sunnyvale, CA). Brightlite and Steadylite HTS luciferase substrates (Perkin Elmer, Wellesley, MA) were added separately to detect the one suitable for the assay. (The luciferase enzyme acted on the firefly substrate D-luciferin in the substrate reagent, which is converted to adenyl oxyluciferin that emits light.) The signals were recorded every 10 min following the addition of luciferase substrate to optimize the time for full signal generation.
A dose-response experiment with 0.01, 0.1, 1.0, 5.0, and 10.0 µM desferrioxamine (molecular weight = 680) was performed under these assay conditions. This iron chelator, which previously limited APP 5′UTR-directed enhancement of translation and reduced APP holoprotein expression, 13, 27 served as a positive control for our screening experiment.
HTS modulators for APP mRNA 5′ ′UTR
Cell plating for HTS assay. After assay optimization, pIRES(APP mRNA 5′UTR)-transfected stable SH-SY5Y cells were trypsinized, harvested, resuspended in culture medium, and strained with a cell strainer (BD Falcon, Bedford, MA) to remove clumped cells and ensure a more equal number of cells in each well. A Multidrop 384-cell dispenser (Thermo Lab Systems, NJ) was used to add 40 µl containing 1000 cells to the 23 columns of black 384-well culture plates. Untransfected SH-SY5Y cells were added to the 24th column. The cells were incubated for 2 h before HTS.
LDDN compound library used for HTS. The compounds of the LDDN library used for HTS were chosen to have an increased probability of oral bioavailability and penetration of the blood-brain barrier. Their selection was done by applying various computational filters, which includes calculations of polar surface area, Lipinski's "rule of five," 28 and filters to reduce common toxicophores and unwanted/non-drug-like functionalities and to maximize molecular diversity.
The compounds included 1) 1670 FDA-approved drugs from Prestwick; 2) 480 purified natural products; 3) 3000 end-blocked tetrapeptides; 4) small molecules purchased from Peakdale (High Peak, UK), 16,000 from Maybridge Plc. (Cornwall, UK), 5000 from CEREP (Paris, France), 7000 from Bionet Research Ltd. (Cornwall, UK), 50,000 from Chemical Diversity Lab (San Diego, CA), 6000 from ENAMINE (Kiev, Ukraine), and 6000 from I.F. Lab Ltd. (presently Life Chemicals Inc., Burlington, Canada); and 5) small molecules from different academic institutions. A large proportion of the LDDN library (60,000 compounds) has been tested successfully for a number of HTS assays. [29] [30] [31] [32] Compound addition. The average molecular weight of the compounds in the LDDN library is 400 (range = 225-600), and they are stored at a stock concentration of 4 mg/ml (based on weight) to approximately 10 mM. For the HTS, the 10-mM compounds were diluted to approximately 1.67 mM in 100% DMSO, and 0.4 µl of this was spotted per well to the first 22 columns of Greiner 384-well plates. The 23rd and 24th columns were spotted with 0.4 µl of 100% DMSO.
This was done with a Multimek 96/384 Channel Automated Pipetter (Beckman Coulter, Fullerton, CA) provided with stack carousel. The plates were covered with plate sealers and stored at -20° C until the day of screening (generally 24 h).
Transfer of compounds to cells and luciferase assay. HTS was carried out using a Beckman Coulter Liquid
Handling System provided with the Biomek Fx Laboratory Automation Workstation. A total of 60 µl/well of DMEM was added to prespotted compound plates, and the plates were shaken to optimally mix the drugs. Aliquots of 10 µl/well of media-containing compound and DMSO were transferred from the Greiner 384-well to the Nunc assay plates containing 40 µl/well of cells and shaken for 5 min. The target average final concentration of the compound library for screening was 2.2 µM. The plates were incubated at 37° C for 48 h. Steadylite HTS substrate (25 µl/well) was added to each well and incubated for 10 min, and luminescence was measured.
The data were uploaded into Activity Base (IDBS Inc., Guildford, UK) and exported to Excel, and the inhibition of luciferase activity was calculated from the luminescence by the formula
where avg. neg. control is the average luminescence calculated from wells with DMSO and untransfected SH-SY5Y cells (column 24) and avg. pos. control is the average of luminescence from the positive control wells containing transfected cells with DMSO (column 23).
To assess for assay quality, the Z′ factor, a dimensionless statistical characteristic for each plate, was calculated using Excel software according to the method developed by Zhang et al. 33 Z′ = 1 -[(3 SD pos. control + 3 SD neg. control)/ (mean pos. control -mean neg. control)],
where SD pos. control is the standard deviation (n = 16) of the positive control (i.e., transfected cells with DMSO) and SD neg. control is the standard deviation (n = 16) of the negative control (i.e., untransfected SH-SY5Y cells with DMSO). Mean pos. control is the mean (n = 16) of the positive control. Mean neg. control is the mean (n = 16) of the negative control. The data for luciferase inhibition and Z′ factor were then plotted in Excel.
Manual confirmation of compound hits inhibiting APP mRNA 5′ ′UTR-driven luciferase
To confirm the HTS-identified compound hits, we manually replicated addition for each hit thrice on 3 different days in 5 wells each time in the 384-well plates with positive and negative controls. The inhibition of luciferase was calculated, and the average of the values obtained by HTS and manual addition was considered.
Viability assay (MTS)
Cell viability was performed by MTS assay (Promega) following the manufacturer's instruction. Briefly, 10 µl MTS reagent was added to each well. As a negative control, cells in some wells were lysed in 10% Triton X-100. The plate was incubated for 2 h at 37°C, and the absorbance was recorded at 490 nm, read in a Spectra Max plate reader (Molecular Devices). Percentage cell viability was calculated by the formula % cell viability = 100 × (absorbance -avg. lysis)/(avg. background -avg. lysis), where avg. background is the average absorbance calculated from wells with DMSO alone and avg. lysis is the average absorbance calculated from lysed cells.
Counterscreen of identified compound hits on PrP mRNA 5′ ′UTR-driven luciferase
For the purpose of counterscreening, pIRES(PrP mRNA 5′UTR)-transfected SH-SY5Y cells were plated in 384-well black plates, and the identified compound hits that were not cytotoxic were manually added to the cells. Each hit was added in 5 wells, and this was repeated twice on 2 different days. There was a positive control and negative control column of cells as described before. The inhibition of luciferase was calculated, and the average of the values obtained was considered.
Determination of dose response for the compounds screened
The pIRES(APP mRNA 5′UTR) luciferase inhibitor compounds obtained from the preliminary HTS were picked up, and the dose-response assay at 0.1, 1.0, and 5.0 µM (based on the exact molecular weights) of the compounds done thrice on 3 different days on the luciferase inhibition of the pIRES(APP mRNA 5′UTR) and pIRES(PrP mRNA 5′UTR) cells was conducted. The data were then plotted in an Excel program.
RESULTS
Assay design and optimization
In the pIRES(APP mRNA 5′UTR) and pIRES(PrP mRNA 5′UTR) plasmid constructs ( Fig. 1) , translation of the luciferase reporter was under the regulation of their respective 5′ untranslated regions. The translation of GFP is from the same RNA molecule but under the control of IRES and served as the internal specificity control.
The constructs were separately stably transfected into an SH-SY5Y neuroblastoma cell line. Upon visual inspection, most cells expressed the construct. Figure 2A is the photo-micrographic representation of GFP fluorescence in a stably transfected SH-SY5Y neuroblastoma cell line. After satisfactory visual observation with GFP, we optimized conditions for high-throughput screen. Ordinarily, bioluminescent assays are done with white plates to maximize the signal. However, for our assay, the signal was very bright in these cells even at low density. Therefore, black plates and the steadylite HTS luciferase substrate were selected for the assay to minimize the problem of "cross-talk."
To optimize the number of cells per well, we serially diluted the cells in black 384-well plates and conducted the luciferase assay. As expected, the luminescence signal (in counts per second [cps]) was proportional to the cell density (Fig. 2B) .
We selected a concentration of 1000 cells/well for our HTS assay because at this cell density, the signal was found to be prominent (average of 20,000 cps) and devoid of cross-talk between wells. Figure 2C depicts the luminescence of pIRES(APP mRNA 5′UTR)-transfected SH-SY5Y in 384-well black plates as compared with the untransfected SH-SY5Y cells at this cell density. The luciferase luminescence of transfected cells was about 1000-fold higher than the untransfected ones, illustrating the specificity of our assay conditions. Desferrioxamine, the positive control drug, had a dosedependent inhibition of APP 5′UTR-driven luciferase expression under the conditions selected for this transfection-based screen (data not shown).
HTS for identification of inhibitors of luciferase in pIRES(APP mRNA 5′ ′UTR)transfected stable SH-SY5Y cell line
An HTS campaign was performed using the 110,000component molecular library of LDDN. The compounds were screened at an average final concentration of 2.2 µM (for details, see the "Compound Addition" section in "Materials and Methods"), and the percentage inhibition of luciferase in the pIRES(APP mRNA 5′UTR) cells was determined. Figure 3A shows the HTS results for the 110,000 compounds of the LDDN library added to pIRES(APP mRNA 5′UTR) stably transfected SH-SY5Y cells. The scatter plot was evaluated, and compounds with greater than 50% inhibition of luciferase at an average of 2.2-µM concentration were subjected for further verification of activity.
We used the statistical calculation for the Z′ factor (equation 2 in the "Materials and Methods" section) to define signal dynamic range and the data variation associated with the luciferase signal measurements. In general, Z′ factors greater than 0.5 indicate excellent quality for an assay. 33 Of the 338 plates tested in our screen, most had a Z′ value of 0.8 to 0.9, and very few had a value between 0.5 and 0.75 (Fig. 3B) . This indicated that our HTS assay was robust and of high quality. The minority plates with lower Z′ values may be due to 1) the cell passage, which might have contributed to a variation in cell condition; 2) variation in signal strength due to freezing and thawing of luciferase substrate; or 3) instrumental errors. Plates with Z′ less than 0.7 were repeated. The edge effect, one of the major factors that decrease the performance level of the HTS assay, 34 was observed to be minimum (Fig. 3C) . The data from 1 representative compoundtreated plate are depicted as a surface graph (raw data plotted in Excel software), with each square corresponding to the luciferase luminescence intensity of each well. Two wells show strong inhibition, and 1 well shows activation. The overall flatness of the surface in the figure depicts the cell-plating consistency, which is unlike the domelike appearance indicative of edge effect. We attribute the evenness to the gas-permeable seals used during the 48-h incubation.
Identification of APP mRNA 5′ ′UTR-driven luciferase inhibitors and elimination of false positives based on HTS information
Of the 110,000 compounds that underwent HTS, 259 (0.235% of compounds screened) at 2.2-µM concentration caused more than 50% inhibition of the luciferase luminescence in pIRES(APP mRNA 5′UTR)-transfected cells. These compounds were then checked for their cytotoxicity. Of these, 82 compounds (32% of the 259 compounds and 0.075% of total compounds screened) had toxicity below 5%. Cellular toxicity was observed with 177 compounds (68% of these 259 compounds), and they have been further classified (Fig. 4) based on their cytotoxicity. The inhibition of luciferase luminescence of APP mRNA 5′UTR-transfected cells by 2.2 µM of the 82 nontoxic compounds (below 5% cytotoxicity) was rechecked manually; 60 (0.055% of those screened) showed 75% to 100% inhibition, and 22 (0.020% of those screened) showed 50% to 75% inhibition.
The inhibitory compounds were predicted to be directed toward 1) the CMV promoter, 2) APP mRNA 5′UTR, or 3) luciferase in the pIRES(APP mRNA 5′UTR) plasmid construct. To eliminate compounds that inhibited through the CMV promoter or through luciferase itself, and to select compounds specifically inhibiting APP mRNA 5′UTR, we performed a counterscreen on the pIRES(PrP mRNA 5′UTR) cells with the 82 inhibitors at an average of 2.2 µM. This strategy was desired to ensure that the hits were indeed specifically APP mRNA 5′UTR inhibitory compounds, causing no change to PrP mRNA 5′UTR conferred expression.
Twenty inhibitors (0.018% of compounds screened) were found to suppress the luciferase signal specifically in pIRES(APP mRNA 5′UTR) cells to a distinctly greater extent (>25%) relative to pIRES(PrP mRNA 5′UTR) cells. The other 62 suppressed the luciferase luminescence of pIRES(PrP mRNA 5′UTR) cells to almost the same extent (<25%) as PIRES(APP mRNA 5′UTR) cells. The inhibition of luciferase expression in pIRES(APP mRNA 5′UTR) cells and in pIRES(PrP mRNA 5′UTR) cells by the 20 inhibitory compounds (with >25% difference in inhibition in the 2 cell lines) is represented graphically as white and black columns, respectively, in the histogram in Figure 5 . Twelve (0.011% of those compounds screened) of the 20 inhibitors caused 50% to 100% more inhibition of luciferase in pIRES(APP mRNA 5′UTR) cells compared to pIRES(PrP mRNA 5′UTR) cells (Fig. 5A) ; the negative inhibition of pIRES(PrP mRNA 5′UTR) cells for compounds 1, 2, and 12 in the figure was considered to be 0. Of these 12 small molecules, 8 (0.0072% of those screened) showed 75% to 100% more inhibition, and 4 (0.0036% of compounds screened) demonstrated 50% to 75% more inhibition of the luciferase signal on pIRES(APP mRNA 5′UTR) cells than on pIRES(PrP mRNA 5′UTR) cells.
There were 8 other compounds (0.0072% of compounds screened) ( Fig. 5B ) that suppressed pIRES(APP mRNA 5′UTR) more than pIRES(PrP mRNA 5′UTR) by 25% to 50%. The inhibitors had no effect on the GFP expression of the cells; that is, the fluorescence seen under the microscope remained unchanged after treatment with compound (not shown). Figure 6A represents the dose response at 0.1, 1.0, and 5 µM of 1 compound hit (designated as 12) (Fig. 5A) on the luciferase signal in pIRES(APP mRNA 5′UTR) cells (bold line) as compared to pIRES(PrP mRNA 5′UTR) cells (broken lines). The inhibitory effect of compound 12 on pIRES(APP mRNA 5′UTR) cells was dose dependent, whereas the pIRES (PrP mRNA 5′UTR) cells showed no inhibition of luciferase activity. For the purpose of comparison, the data in Figure 6B show the inhibitory effect of compound 8 of Figure 5B . The compound inhibited luciferase in both pIRES(PrP mRNA 5′UTR) and pIRES(APP mRNA 5′UTR) cell lines, but inhibition on APP 5′UTR-transfected cells was significantly higher at 5 µM.
Representative dose response for compounds screened
DISCUSSION
The search for novel therapeutics for AD is ongoing. We have previously identified APP mRNA 5′UTR stem loop to be a significant regulator of the levels of APP holoprotein and Aβ 
FIG. 5.
Identification of specific amyloid precursor protein (APP) mRNA 5′UTR compound inhibitors. (A) Compounds that inhibited APP mRNA 5′UTR >50% relative to PrP mRNA 5′UTR. The APP mRNA 5′UTR-directed inhibitory compounds that were identified by high-throughput screening (HTS) and subsequent manual rechecking were counterscreened using PrP mRNA 5′UTR-transfected cells. Twelve compound hits were obtained that specifically inhibited APP mRNA 5′UTR-driven luciferase greater than PrP mRNA 5′UTR-driven ones by more than 50%. Their percentage inhibition of luciferase expression in the pIRES(APP mRNA 5′UTR) cells (white column) and in the control pIRES(PrP mRNA 5′UTR) cells (black column) are represented here; data are an average of readings from 15 wells from 3 experiments performed on 3 different days (p = 0.0001). (B) Compounds that inhibited APP mRNA 5′UTR >25% relative to PrP mRNA 5′UTR. Percentage inhibition of 8 compounds that showed very strong inhibition in the APP mRNA 5′UTR (white) and weaker inhibition in the control PrP mRNA 5′UTR cells (black) are represented. peptide production. [20] [21] [22] [23] In this regard, our aim was to identify compounds targeted toward this mRNA, which may well serve as therapeutics to limit amyloid production.
An HTS campaign with 110,000 LDDN compounds was established with pIRES(APP mRNA 5′UTR)-transfected SH-SY5Y cells, with luciferase being the primary reporter gene. The assay retained its reliability as determined by the large Z′ factor, indicative of an excellent overall assay. To confirm accuracy of the screening conditions, we achieved dose-dependent inhibition of APP 5′UTR activity with the drug desferrioxamine (molecular weight = 680) as previously reported. 13, 27 Through the robust 384-well plate HTS assay, we identified 259 compounds that inhibited the luciferase reporter gene expression. Of these, 177 compounds (68% of the 259 compounds) were cytotoxic. The remaining 82 compounds (32% of the 259 compounds) that were not cytotoxic were rechecked manually for their luciferase suppression on pIRES(APP mRNA 5′UTR) cells. These manually rechecked compounds (0.075% . 5B ) that inhibits luciferase in the pIRES(APP mRNA 5′UTR) cells to a higher extent than pIRES(PrP mRNA 5′UTR) cells. of compounds screened) retained their inhibitory property to almost the same extent (about 90%) as during HTS (data for all compounds not shown). This further supports the authenticity of the HTS conducted. A counterscreen with the pIRES(PrP mRNA 5′UTR) cells was then employed as a control to ensure screening selectivity toward the APP mRNA 5′UTR.
Although the prions are not members of the APP super family, they cause neurodegenerative diseases, including bovine spongiform encephalopathy 35 and Creutzfeldt-Jakob disease. 36 Interestingly, the human prion protein gene promoter shares features with the human APP promoter. 37 The presence of the "CAGA" box in the PrP genes 5′UTRs was also investigated. 14 By application of the algorithm, highly conserved hairpins that might well affect translation and thereby conformation of PrP were found in the prion-protein mRNA. 38 Therefore, the PrP mRNA 5′UTR was a rigorous negative control for our APP mRNA 5′UTR-directed assay.
The counterscreening of the 82 inhibitors with pIRES(PrP mRNA 5′UTR)-transfected cells led to the identification of 12 compounds that specifically suppressed APP mRNA 5′UTR expression by more than 50% as compared with PrP mRNA 5′UTR. Of these 12 compounds, 8 showed 75% to 100% more inhibition and 4 showed 50% to 75% more inhibition of the luciferase signal on pIRES(APP mRNA 5′UTR) cells relative to pIRES(PrP mRNA 5′UTR) cells. The screen also includes potentially interesting chemical compounds, such as compound 1 (Fig. 5A) , that suppressed APP mRNA 5′UTR expression without inhibiting PrP mRNA 5′UTR at all. All the 12 compounds are being further followed up with dose response in both the cell lines. These 12 compounds account for 0.011% of those screened. The convergence to 0.011% of 110,000 LDDN compounds to be identified as APP mRNA 5′UTR inhibitor hits (suppressing more than 50%) and elimination of 99.989% of the compounds was indicative of the specificity and accuracy of the methods adopted, in addition to the high stringency.
Through the HTS, we had identified 435 activators that enhanced the luciferase signal in pIRES(APP mRNA 5′UTR) cells, as evident from Figure 3A . But the compounds showed equal activation of luciferase in the pIRES(PrP mRNA 5′UTR) cells and pIRES(APP mRNA 5′UTR) cells. To partially explain the phenomenon, we noted that the PrP and APP are both copper-zinc metalloproteins, 27, 39, 40 and the mechanism by which compounds influence expression through their 5′UTRs in the SH-SY5Y cells may overlap. In this regard, the APP mRNA 5′UTR inhibitor hits were identified that generated no/low reduction of PrP mRNA 5′UTR conferred expression. However, the APP mRNA 5′UTR activators were found not to exert differential action via the PrP mRNA 5′UTR. Consistent with this, one model is that each sequence may bind to a common transacting factor in such a way that a subset of APP mRNA 5′UTR inhibitors was specific to their target, whereas no such subset existed for the PrP mRNA 5′UTR activators screened.
Further characterization of the inhibitory compounds is currently under way, correlating their IC 50 values with their capacity to down-regulate APP translation and Aβ secretion and their effect on neuroprotective APP secretion. The Western blot experiments to measure the resultant decrease in APP protein so far indicate that some of the compound hits reduce APP holoprotein levels in SH-SY5Y cells (data not shown). Some of the analogs of the hits will also be examined to determine the structure activity relationship. The compound hits will also help to generate mechanistic information about the translational control of APP mRNA and the importance of the interaction of IRP-1 and IRP-2 with 5′UTR of APP mRNA through computational molecular modeling approaches. 41 
CONCLUSION
In Western countries, AD is the most common form of dementia with no therapy in hand. Selective reduction of APP and Aβ production is thought to be therapeutically beneficial in AD. Thus, the identification of the novel APP mRNA 5′UTR inhibitors reported here is expected to hold therapeutic promise at least for those retaining long-term bioactivity.
